When discounted playing cards might help reduce the burden of high drug expenses during the short term, they don't tackle the systemic difficulties driving up prescription selling prices while in the U.S. Broader policy alterations could deal with the root leads to of soaring drug rates, for instance insufficient transparency in pricing and the pos